.Nature Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a mean consequence of 11 months, individuals with metastatic intestinal tumors who received biomarker-matched treatments based upon flowing tumor DNA profiling presented a higher medical advantage than those acquiring unmatched treatment.